After receiving clinical research ethics committee approval (07/43; 25/05/2023), we reviewed the data from a routinely and prospectively maintained clinical database. We conducted a retrospective ...

Prostate cancer is the most common malignant tumor in men, accounting for 29% of male neoplasm diagnoses in the United States alone. Radical prostatectomy remains the preferred treatment for localized ...

This study aims to compare the perioperative outcomes, postoperative urinary control rates, and positive surgical margin (PSM) rates of robot-assisted laparoscopic radical prostatectomy using a ...

With Men’s Health Week approaching, it is a good time to encourage open discussions about various health conditions, particularly prostate health. Driven by embarrassment, misconceptions, and a lack ...

Up to 72% of patients with prostate cancer who undergo radical prostatectomy experience urinary incontinence in the first 3 months after surgery. Up to 72% of patients experience urinary incontinence ...

Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.

Wrapping dehydrated human amniotic membrane around nerve and anastomotic tissue during robotic prostatectomy was associated with faster recovery of erectile function, a 10-year, single-center study ...

For many men navigating the challenging journey of prostate cancer, radical prostatectomy represents a life-saving sur ...

of erectile function 1 year after surgery is associated with higher technical skills and increased use of specific surgical gestures by the operating surgeon. The findings were published in JAMA ...

Stereotactic body radiotherapy as salvage therapy after radical prostatectomy was well tolerated. Toxic effects were comparable to a historical cohort of patients receiving conventionally fractionated ...

Tiberias, Israel, June 2, 2026-- OhhMed Medical Ltd., a pioneering medical technology firm specialising in male urology, today announced the initiation of a clinical trial in the United Kingdom. The ...

Adding apalutamide to ADT in the adjuvant and neoadjuvant settings improves outcomes in prostate cancer patients undergoing radical prostatectomy.